Efficacy of Triclosan-coated Sutures in the Episiotomy
Launched by UNIVERSITY TUNIS EL MANAR · Jul 27, 2016
Trial Information
Current as of July 05, 2025
Unknown status
Keywords
ClinConnect Summary
Women undergoing planned were randomized to either episiotomy suture with VICRYL PLUS or VICRYL. The primary outcome measures were number of sutures used and the development of hematoma, seroma, surgical site infection (SSI) or wound disruption one week after episiotomy. Secondary outcome measures were the cost of the treatment with or without infection, and scar evaluation (wound complication).
Data were analyzed according to the intention to treat principle.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant women who had had an episiotomy at the delivery
- • vaginal delivery
- • no further perineal or vaginal lesions present
- Exclusion Criteria:
- • collagen disease
- • known immunodeficiency
- • Clinical signs of infection at the time of episiotomy
- • History of keloids and a medical disorder that could affect wound healing
- • Hypersensitivity to any of the suture materials used in the protocol
- • Diabetes mellitus
- • Disorders requiring chronic corticosteroid use or immunosuppression
- • Instrumental extraction
About University Tunis El Manar
The University of Tunis El Manar is a prestigious academic institution dedicated to advancing research and education in the medical and health sciences. As a clinical trial sponsor, it plays a pivotal role in fostering innovative research initiatives aimed at improving patient care and outcomes. The university collaborates with leading researchers and healthcare professionals to design and implement rigorous clinical studies that adhere to the highest ethical and regulatory standards. Through its commitment to scientific excellence and community health, the University of Tunis El Manar seeks to contribute valuable insights to the global medical field and enhance the quality of life in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bizerte, , Tunisia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials